- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07905183
A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs (ENABLE-2)
A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs
The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Enliven Medical Information
- Telefonní číslo: +1 6505475814
- E-mail: MedInfo@enliventherapeutics.com
Studijní místa
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Nábor
- Winship Cancer Institute
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46260
- Nábor
- Investigative Clinical Research of Indiana, LLC
-
-
New Jersey
-
Morristown, New Jersey, Spojené státy, 07960
- Nábor
- Atlantic Health System
-
-
Utah
-
Ogden, Utah, Spojené státy, 84405
- Nábor
- Community Center Trials of Utah
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male or female at least 18 years of age
- Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
- Prior treatment with 1 or more BCR::ABL1 TKI(s)
- Failure or intolerance on the immediate prior TKI
- Adequate end organ function as measured by blood tests
Exclusion Criteria:
- Known T315I mutation
- Known second chronic phase of CML after previous progression to accelerated or blast phase
- Any serious or uncontrolled medical disorder
- QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
- Previous treatment with a hematopoietic stem-cell transplantation
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: ELVN-001
ELVN-001 |
ELVN-001 orally daily |
|
Aktivní komparátor: Investigator-selected TKI
Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib |
TKI orally daily
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Časové okno: 24 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
24 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
Časové okno: 96 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
96 weeks
|
|
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Validated questionnaires will be used to assess disease-related symptoms, functioning, and tolerability. |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
The time to MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR |
planned total follow-up duration of 5 years
|
|
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Duration of MMR is defined as the time between the date of the first achievement of MMR and the earliest date of loss of MMR or CML-related death |
planned total follow-up duration of 5 years
|
|
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
BCR::ABL1 transcript levels are measured by quantitative polymerase chain reaction (qPCR). The ratio is calculated for BCR::ABL/ABL1 based on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Time to treatment failure is defined as the time from randomization to the first date of any of the following events: treatment failure as defined per protocol |
planned total follow-up duration of 5 years
|
|
Progression-free survival - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Progression-free survival is defined as the time from randomization to the earliest occurrence of progression or death from any cause |
planned total follow-up duration of 5 years
|
|
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
OS is defined as the time from randomization to death from any cause |
planned total follow-up duration of 5 years
|
|
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MR4 is defined as a ratio BCR::ABL/ABL1 ≤ 0.01% on the International Scale and MR4.5 is defined as a ratio BCR::ABL/ABL1 ≤ 0.0032% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
This is defined as the time from randomization to discontinuation of study treatment due to an adverse event |
planned total follow-up duration of 5 years
|
|
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
Časové okno: planned total follow-up duration of 5 years
|
Characteristics of AEs will be evaluated to assess safety and tolerability profiles |
planned total follow-up duration of 5 years
|
|
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints
Časové okno: planned total follow-up duration of 5 years
|
Relevant pharmacokinetic parameters will be evaluated |
planned total follow-up duration of 5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Patologické procesy
- Novotvary
- Chronické onemocnění
- Atributy nemoci
- Novotvary podle histologického typu
- Hematologická onemocnění
- Leukémie, myeloidní
- Nemoci kostní dřeně
- Leukémie
- Myeloproliferativní poruchy
- Translokace, Genetika
- Chromozomové aberace
- Patologické stavy, příznaky a symptomy
- Hemická a lymfatická onemocnění
- Leukémie, myeloidní, chronická, BCR-ABL pozitivní
- Chromozom Philadelphia
- Leukémie, myeloidní, chronická fáze
- Sloučeniny síry
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Thiazoles
- Azoly
- Pyrimidiny
- Dasatinib
- Nilotinib
- Bosutinib
Další identifikační čísla studie
- ELVN-001-301
- 2026-526266-25-00 (Ctis)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .